Table 1.
Summary of the model parameter values and sources for Brazilian cities.
| Parameter | Description | Base case value (range) | Source |
|---|---|---|---|
| c_out_priv | Private outpatient treatment cost (BRL) | 414.39 (200.00–900.00) | ANS; CMED |
| c_out_pub | Cost of public outpatient treatment (BRL) | 367.01 (123.61–572.41) | BPS; SIGTAP |
| c_hosp_priv | Private Hospital Treatment Cost (BRL) | 2344.32 (1875.46–2813.18) | Machado (2019)22 |
| c_hosp_pub_nonsevere | Cost of public hospital treatment for non-severe dengue (BRL) | 1327.88 (1062.30–1593.45) | SIH/DATASUSa |
| c_hosp_pub_severe | Cost of public hospital treatment for severe dengue (BRL) | 3488.52 (2790.81–4186.22) | SIH/DATASUSa |
| c_program_dengue | Cost of Dengue Control Program (per inhabitant) (BRL) | 34.37 (27.49–41.24) | Taliberti (2010)23; Santos (2015)24 |
| c_wolbachia | Wolbachia method implementation incremental cost (per inhabitant) (BRL) | 12.74 (12.74–35.75) | WMP (2023) |
| c_ind_death | Indirect cost of productivity loss due to premature death (BRL) | 937,922.86 (750,338.29–1,125,507.43) | ISPER25,a |
| c_ind_out | Indirect cost of productivity loss due to outpatient treatment (BRL) | 1039.91 (831.93–1247.90) | ISPER25,a |
| c_ind_hosp | Indirect cost of productivity loss due to inpatient treatment (BRL) | 2244.02 (1795.21–2692.82) | ISPER25,a |
| multiplication_factor | Case expansion multiplier due to underreport in SINAN | 12 (9.8–14.9) | Silva (2016)26 |
| p_inapparent | Proportion of inapparent infections (asymptomatic or self-care) | 0.6060 (0.4848–0.7272) | Azeredo (2017)27; Vazquez-Prokopec (2023)28 |
| p_outpatient | Proportion of outpatient cases (symptomatic) | 0.3536 (0.28288–0.42432) | SINAN/DATASUSa |
| p_hospital | Proportion of hospitalized cases | 0.0404 (0.03232–0.04848) | SINAN/DATASUSa |
| p_self_care | Proportion of inapparent infections having symptoms (self-care) | 0.125 (0.0–0.125) | Aguiar (2021)29 |
| p_nonsevere | Proportion of severe dengue in hospitalized cases | 0.1466 (0.11728–0.17592) | SIH/DATASUSa |
| p_death_overall | Probability of general death according to age | 0.0023 (0.00184–0.00276) | IBGE, 2021a |
| p_death_hospital | Probability of death in hospitalized cases (case-fatality rate) | 0.0165 (0.0132–0.0198) | SIH/DATASUSa |
| d_weight_dengue_severe | Disability weight in severe cases of dengue | 0.133 (0.1064–0.1596) | GBD (2019)30 |
| d_weight_dengue_moderate | Disability weight in moderate cases of dengue | 0.051 (0.0408–0.0612) | GBD (2019)30 |
| d_weight_fatigue | Disability weight in cases of post-dengue sequelae | 0.219 (0.1752–0.2628) | GBD (2019)30 |
| RR_wolbachia | Relative risk of dengue incidence with the Wolbachia method | 0.229 (0.1832–0.2748) | Utarini (2021)6 |
| time_fatigue | Average duration of persistent syndrome (83.6 days) in years | 0.233 (0.1864–0.2796) | Teixeira (2017)31 |
| time_moderate | Average duration of moderate syndrome (7 days) in years | 0.019 (0.0152–0.0228) | Xavier (2020)32 |
| time_severe | Average duration of serious conditions (15 days) in years | 0.041 (0.0328–0.0492) | Xavier (2020)32 |
| Discount | Annual discount rate | 0.050 (0.00–0.010) | Brazil (2014)12 |
ANS: National Supplementary Health Agency; CMED: Drug Market Regulation Chamber; BPS: Health Prices Database; ISPER: Public Employment and Income System; SIGTAP: Public Health Procedures Table; SIH/DATASUS: Hospital Information System; SINAN/DATASUS: Notifiable Diseases Information System; WMP: World Mosquito Program.
a
Overall value for illustrative purpose, actual values adopting mean costs according to age range.